Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom
Year: 2026
Type: article
Abstract: Trametinib (MEK inhibitor) shows efficacy in refractory and high-risk adult histiocytic neoplasms. At a median follow-up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
Source: British Journal of Haematology
DOI: 10.1111/bjh.70617
Institutions: University College London Hospitals NHS Foundation Trust, University College London, Leeds Teaching Hospitals NHS Trust, University of East Anglia, Norfolk and Norwich University Hospital, University Hospitals Bristol NHS Foundation Trust, Great Western Hospital, Great Western Hospitals NHS Foundation Trust, Royal Blackburn Teaching Hospital, Cambridge University Hospitals NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust, Clatterbridge Cancer Centre NHS Foundation Trust, University Hospital of Wales, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7165050496